Maxwell Skor
Stock Analyst at Morgan Stanley
(4.78)
# 552
Out of 4,651 analysts
230
Total ratings
74%
Success rate
27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Rated: Buy | $275 | $248.50 | +10.66% | 26 | Aug 14, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $13 | $7.59 | +71.28% | 1 | Aug 13, 2026 | |
| AVIR Atea Pharmaceuticals | Rated: Hold | $6 → $7 | $5.12 | +36.72% | 11 | Aug 13, 2026 | |
| PHVS Pharvaris | Rated: Buy | $46 | $35.14 | +30.90% | 88 | Aug 13, 2026 | |
| INSM Insmed | Rated: Buy | $212 → $218 | $123.74 | +76.18% | 25 | Aug 6, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $67 | $26.49 | +152.93% | 12 | Aug 4, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $60 | $53.55 | +12.04% | 2 | Aug 4, 2026 | |
| CYTK Cytokinetics | Rated: Buy | $103 | $74.13 | +38.95% | 21 | Jul 23, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $115 | $113.04 | +1.73% | 3 | Jul 22, 2026 | |
| TCRX TScan Therapeutics | Maintained: Hold | n/a | $0.7788 | - | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $87 → $80 | $84.70 | -5.55% | 7 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $12 | $3.90 | +207.69% | 8 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.55 | +238.03% | 3 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.70 | - | 6 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.7209 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.591 | n/a | 1 | Sep 25, 2023 |
Ascendis Pharma
Aug 14, 2026
Rated: Buy
Price Target: $275
Current: $248.50
Upside: +10.66%
Achieve Life Sciences
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $7.59
Upside: +71.28%
Atea Pharmaceuticals
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $5.12
Upside: +36.72%
Pharvaris
Aug 13, 2026
Rated: Buy
Price Target: $46
Current: $35.14
Upside: +30.90%
Insmed
Aug 6, 2026
Rated: Buy
Price Target: $212 → $218
Current: $123.74
Upside: +76.18%
Ultragenyx Pharmaceutical
Aug 4, 2026
Maintained: Buy
Price Target: $67
Current: $26.49
Upside: +152.93%
CRISPR Therapeutics AG
Aug 4, 2026
Maintained: Hold
Price Target: $60
Current: $53.55
Upside: +12.04%
Cytokinetics
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $74.13
Upside: +38.95%
Monopar Therapeutics
Jul 22, 2026
Maintained: Buy
Price Target: $115
Current: $113.04
Upside: +1.73%
TScan Therapeutics
Jun 22, 2026
Maintained: Hold
Price Target: n/a
Current: $0.7788
Upside: -
Jun 15, 2026
Maintained: Buy
Price Target: $87 → $80
Current: $84.70
Upside: -5.55%
May 18, 2026
Maintained: Hold
Price Target: $12
Current: $3.90
Upside: +207.69%
May 18, 2026
Maintained: Buy
Price Target: $12
Current: $3.55
Upside: +238.03%
Aug 22, 2025
Maintained: Hold
Price Target: n/a
Current: $3.70
Upside: -
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.7209
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.591
Upside: n/a